AbL Diagnostics SA Cash Flow Conversion Efficiency
AbL Diagnostics SA cash flow conversion efficiency. Based on the latest financial reports, AbL Diagnostics SA (ABLD) has a cash flow conversion efficiency ratio of 0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€479.46K ≈ $560.54K USD) by net assets (€6.93 Million ≈ $8.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of AbL Diagnostics SA (2017–2025)
Cash flow conversion efficiency of AbL Diagnostics SA from 2017 to 2025. This chart illustrates how AbL Diagnostics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for AbL Diagnostics SA for real-time trading data and today's change.
AbL Diagnostics SA Cash Flow Conversion Ratio Explained
AbL Diagnostics SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
AbL Diagnostics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbL Diagnostics SA ranked by their cash flow conversion efficiency. Also see AbL Diagnostics SA market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RMB Holdings Ltd
JSE:RMH
|
-0.038x |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
0.085x |
|
Feerum S.A.
WAR:FEE
|
0.073x |
|
Indah Prakasa Sentosa PT Tbk
JK:INPS
|
-0.124x |
|
Dominari Holdings Inc.
NASDAQ:DOMH
|
-0.452x |
|
Inbest Prime VI Inmuebles Socimi SA
MC:YINB6
|
0.017x |
|
Yuyu Pharma
KO:000220
|
0.006x |
|
BII Railway Transportation Technology Holdings Company Limited
F:CN6
|
-0.008x |
Annual Cash Flow Conversion Efficiency for AbL Diagnostics SA (2017–2025)
The table below shows the annual cash flow conversion efficiency of AbL Diagnostics SA from 2017 to 2025. Review ABLD FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.63 Million ≈ $8.92 Million |
€1.51 Million ≈ $1.76 Million |
0.198x | +209.34% |
| 2024-12-31 | €7.49 Million ≈ $8.75 Million |
€-1.35 Million ≈ $-1.58 Million |
-0.181x | -231.96% |
| 2023-12-31 | €6.77 Million ≈ $7.91 Million |
€926.43K ≈ $1.08 Million |
0.137x | +1804.30% |
| 2022-12-31 | €6.75 Million ≈ $7.90 Million |
€-54.25K ≈ $-63.42K |
-0.008x | +62.89% |
| 2021-12-31 | €2.62 Million ≈ $3.06 Million |
€-56.69K ≈ $-66.28K |
-0.022x | -273.21% |
| 2020-12-31 | €2.36 Million ≈ $2.76 Million |
€29.51K ≈ $34.50K |
0.012x | +131.83% |
| 2019-12-31 | €7.09 Million ≈ $8.29 Million |
€-278.40K ≈ $-325.48K |
-0.039x | -446.32% |
| 2018-12-31 | €7.15 Million ≈ $8.36 Million |
€81.10K ≈ $94.82K |
0.011x | -87.62% |
| 2017-12-31 | €7.37 Million ≈ $8.62 Million |
€675.20K ≈ $789.38K |
0.092x | -- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more